Open access
82
Views
1
CrossRef citations to date
0
Altmetric
Original Research
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
Soham Shukla1 Value Evidence and Outcomes, GSK, Collegeville, PA, USA
https://orcid.org/0000-0002-4139-0856View further author information
Dhvani Shah2 ICON, New York, NY, USAView further author information
, Alan Martin3 Value Evidence and Outcomes, GSK, Brentford, Middlesex, UK
https://orcid.org/0000-0002-3673-3383View further author information
Nancy A Risebrough4 Global Health Economics, and Outcomes Research and Epidemiology, ICON, Toronto, ON, CanadaView further author information
, Robyn Kendall5 Global Health Economics, and Outcomes Research and Epidemiology, ICON, Vancouver, BC, Canada
https://orcid.org/0000-0001-6331-5497View further author information
Claus F Vogelmeier6 Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Marburg, GermanyView further author information
, Isabelle Boucot3 Value Evidence and Outcomes, GSK, Brentford, Middlesex, UK
https://orcid.org/0000-0003-0410-4969View further author information
Lee Tombs7 Precise Approach Ltd, Contingent Worker on Assignment at GSK, Brentford, Middlesex, UKView further author information
, Leif Bjermer8 Respiratory Medicine and Allergology, Lund University, Lund, Sweden
https://orcid.org/0000-0002-3441-8099View further author information
Paul W Jones3 Value Evidence and Outcomes, GSK, Brentford, Middlesex, UK
https://orcid.org/0000-0001-6087-9182View further author information
Edward Kerwin9 Altitude Clinical Consulting and Clinical Research Institute of Southern Oregon, Medford, OR, USA
https://orcid.org/0000-0002-1697-9036View further author information
Chris Compton3 Value Evidence and Outcomes, GSK, Brentford, Middlesex, UKView further author information
, François Maltais10 Centre de Pneumologie, Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, QC, Canada
https://orcid.org/0000-0002-6809-4651View further author information
David A Lipson11 Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;12 Respiratory Clinical Sciences, GSK, Collegeville, PA, USA
https://orcid.org/0000-0001-6732-4593View further author information
Afisi S Ismaila1 Value Evidence and Outcomes, GSK, Collegeville, PA, USA;13 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, CanadaCorrespondence[email protected]
https://orcid.org/0000-0002-2876-8308View further author information
Pages 3105-3118
|
Published online: 13 Nov 2021
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.